King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

King Pharmaceuticals vs. Alpharma

In August 2008, King Pharmaceuticals tried to woo Alpharma with $1.38 billion cash offer. King wasn't prepared to take no for an answer, and it was ready to get hostile if necessary to push the acquisition through.

But Alpharma wasn't as enthusiastic and rejected the offer. Alpharma claimed it had other companies interested in a buyout, but King pushed forward with the hostile bid. King also threatened a proxy battle if Alpharma continued to reject its offers.

Despite Alpharma's repeated objections, a $1.6 billion offer eventually piqued its interest

King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.